What is Nolotil and Usual Dose
Nolotil is metamizole (also known as dipyrone), a non-opioid analgesic and antipyretic medication used for moderate to severe pain and fever, with usual adult doses ranging from 500-1000 mg orally every 6-8 hours, not exceeding 4 grams daily.
Drug Classification and Mechanism
Metamizole is a pyrazolone derivative that functions as a prodrug—it has no analgesic activity until converted in the body to two active metabolites: 4-methylaminoantipyrine and 4-aminoantipyrine 1. The parent drug is well absorbed from the small intestine, but only these active metabolites (not the parent compound) are detectable in blood 1.
Key pharmacologic properties include:
- Strong analgesic effect comparable to opioids like tramadol, pentazocine, and pethidine when given in equipotent doses 1
- Significant antipyretic activity
- Spasmolytic effects on smooth muscle (sphincter of Oddi, urinary tract, gallbladder) comparable to butylscopolamine 1
- No anti-inflammatory activity at clinical doses, distinguishing it from NSAIDs 1
- Significant antiplatelet effects similar to aspirin 1
Standard Dosing
Adults (Oral Administration)
- Initial dose: 500-1000 mg 2
- Frequency: Every 6-8 hours as needed
- Maximum daily dose: 4000 mg (4 grams) 1
- Mean prescribed daily dose in clinical practice: 2.7 grams 3
Intravenous Administration in Children
- Children 1-6 years: 10-20 mg/kg 4
- Infants <12 months: 5 mg/kg (reduced dose due to increased exposure) 4
The FDA label reference 5 appears to describe a different formulation (possibly diphenhydramine given the "sleeplessness" indication 5), not metamizole/Nolotil.
Clinical Applications
Metamizole is indicated for 1:
- Post-surgical pain
- Patient-controlled analgesia (PCA)
- Cancer pain
- Post-traumatic pain
- Pain from myocardial infarction
- Craniocerebral trauma pain
- Pain from invasive diagnostic procedures
- Neuromuscular pain
- Headache and migraine 2
- Colic attacks (due to combined spasmolytic and analgesic effects)
- Fever unresponsive to other antipyretics
Critical Safety Considerations
Agranulocytosis Risk - The Major Concern
This is the most serious adverse effect and the reason metamizole was withdrawn in many countries. Recent pharmacovigilance data shows:
- Risk estimates vary: approximately 1 in 31,000 inpatients and 1 in 1,400 outpatients 3
- Higher reporting likelihood compared to other drugs known to cause agranulocytosis (ROR 5.50 vs clozapine, 41.7 vs NSAIDs) 6
- Most cases occur with prolonged use - 96% of inpatients received it for <1 week, while 38% of outpatients received it for >15 days 3
- Onset can be rapid - as early as 5 days after starting treatment 7
Prescribing Precautions
Limit duration of use:
- Approved for short-term use only
- Most inpatient use should be <1 week 3
- Prolonged outpatient use (>15 days) carries increased agranulocytosis risk 3
Patient monitoring:
- Educate patients about warning signs: fever, sore throat, mouth ulcers, malaise
- Consider baseline and periodic complete blood counts for longer courses
- Immediate discontinuation if agranulocytosis suspected 7
Drug Interactions
Metamizole has moderate CYP-inducing properties and can significantly reduce exposure to:
- Voriconazole and posaconazole (antifungal triazoles) - avoid concomitant use or perform frequent therapeutic drug monitoring 8
- Potentially other CYP-metabolized drugs
Minimal interactions otherwise - one advantage over many other analgesics 1
Comparative Efficacy
In controlled trials 2:
- 500 mg and 1000 mg metamizole showed highly significant analgesic efficacy vs placebo for tension-type headache
- Trend toward earlier onset and more profound pain relief compared to 1000 mg aspirin
- Relative potency to tramadol approximately 1:23 (meaning metamizole is less potent) 9
Pharmacokinetic Profile
- Onset: Rapid absorption, with metamizole not detectable in plasma (only active metabolites present) 10
- Terminal half-life of active metabolites: Approximately 2.9 hours 10
- Duration of analgesia: 3-4 hours for most doses 9
- Age-related changes: Infants <1 year show increased exposure requiring dose reduction 4
Bottom Line for Clinical Practice
Metamizole is an effective analgesic for moderate to severe pain and fever, but its use must be restricted to short-term treatment (<1 week preferred) due to agranulocytosis risk. The standard adult dose is 500-1000 mg every 6-8 hours (maximum 4 g/day). Given the availability of safer alternatives with comparable efficacy, metamizole should be reserved for cases where other analgesics are ineffective or contraindicated 6. Patients must be counseled about warning signs of agranulocytosis and instructed to stop the medication immediately if symptoms develop.